Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
SABCS 2022
;
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
➡️⬅️
@BTOGORG #BTOG24 #LungCancer #LCSM
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operabilit...
ow.ly
🫁Exciting insights from @CharlesSwanton at #BTOG24 on the link between air pollution and lung cancer initiation, shedding light on tumor formation mechanisms in never smokers:
➡️⬅️
@CR_UK @BTOGORG #LCSM #NSCLC
Lung cancer initiation: towards molecular cancer prevention
Charles Swanton, Francis Crick Institute in London, discusses his research on the initiation and progression of lung ...
ow.ly
Missing #BTOG24? Don’t worry, we’ve got plenty of key highlights and coverage over at http://VJOncology.com!
Click here ➡️http://www.vjoncology.com/event/btog-2024
@BTOGORG #LungCancer #LCSM #NSCLC #SCLC #Mesothelioma
Have you got #ESMOBreast24 in your diary yet?
Less than a month to go until we get to see much awaited updates in #breastcancer!!
🗓️15th - 17th May 🗓️
@myESMO #bcsm
🎥Natasha Leighl, MD, from @UofT shares insights from the CHRYSALIS trial at #AACR24, revealing promising responses to amivantamab in pts w/ #NSCLC, with notable exceptions in KRAS or HER2 mutations:
➡️⬅️
#LungCancer #CTSM #ImmunoOnc
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT0...
ow.ly
SABCS 2022
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
➡️⬅️
@BTOGORG #BTOG24 #LungCancer #LCSM
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operabilit...
ow.ly
🫁Exciting insights from @CharlesSwanton at #BTOG24 on the link between air pollution and lung cancer initiation, shedding light on tumor formation mechanisms in never smokers:
➡️⬅️
@CR_UK @BTOGORG #LCSM #NSCLC
Lung cancer initiation: towards molecular cancer prevention
Charles Swanton, Francis Crick Institute in London, discusses his research on the initiation and progression of lung ...
ow.ly
Missing #BTOG24? Don’t worry, we’ve got plenty of key highlights and coverage over at http://VJOncology.com!
Click here ➡️http://www.vjoncology.com/event/btog-2024
@BTOGORG #LungCancer #LCSM #NSCLC #SCLC #Mesothelioma
Have you got #ESMOBreast24 in your diary yet?
Less than a month to go until we get to see much awaited updates in #breastcancer!!
🗓️15th - 17th May 🗓️
@myESMO #bcsm
🎥Natasha Leighl, MD, from @UofT shares insights from the CHRYSALIS trial at #AACR24, revealing promising responses to amivantamab in pts w/ #NSCLC, with notable exceptions in KRAS or HER2 mutations:
➡️⬅️
#LungCancer #CTSM #ImmunoOnc
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT0...
ow.ly
